drugset

drugset / Trial / NCT00191971

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

NCT00191971 ↗

Phase 2 Completed 40 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium

Timeline

Start: 2004-01
Primary completion: —
Completion: 2006-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	—	—

Indications